This announcement is a separate document:
6-K: Arexvy, Gsk's Respiratory Syncytial Virus Vaccine, Receives Positive European Medicines Agency Chmp Opinion for Adults Aged 50-59 at Increased Risk for Rsv Disease
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.